search
Back to results

Antiseptic Irrigation for Pleural Infection

Primary Purpose

Pleural Infection

Status
Completed
Phase
Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Povidone-Iodine pleural irrigation
Sponsored by
Alexandria University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pleural Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adult patients admitted to hospital with pleural infection and had a chest tube inserted for treatment of the infection. Pleural infection will be defined by the presence of one of the following: a) the presence of pus in the pleural space; b) positive pleural fluid gram stain or culture; or c) pleural fluid pH < 7.2 or pleural fluid glucose < 40 mg/dL in the setting of acute respiratory infection.
  • Pleural collection is unilocular on pre-drainage imaging. Presence of septations on ultrasound examination is allowed.

Exclusion Criteria:

  • Known or suspected thyroid disease
  • Allergy to iodine
  • Persistent large collection on follow up imaging 24-48 of post tube insertion that requires another drainage procedure

Sites / Locations

  • Alexandria University Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Pleural irrigation with antiseptic

No pleural irrigation

Arm Description

Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.

Standard care

Outcomes

Primary Outcome Measures

Incidence of adverse events
Number of subjects with any adverse event (new chest pain, fever, dyspnoea or oxygen desaturation)
Time to chest tube removal
Number of days from tube insertion to tube removal

Secondary Outcome Measures

Time to defervescence
Numbers of days until resolution of fever
Length of hospital stay
Number of days from admission/diagnosis until discharge from hospital
Incidence of need for additional aspiration/tubes
Number of patients requiring additional drainage procedures during hospital admission
Incidence of medical treatment of failure
Number of patients requiring surgical intervention

Full Information

First Posted
February 13, 2021
Last Updated
August 29, 2022
Sponsor
Alexandria University
search

1. Study Identification

Unique Protocol Identification Number
NCT04761133
Brief Title
Antiseptic Irrigation for Pleural Infection
Official Title
Antiseptic Pleural Irrigation for Patients With Pleural Infection
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
March 4, 2021 (Actual)
Primary Completion Date
July 31, 2021 (Actual)
Study Completion Date
August 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Alexandria University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The antiseptic povidone-iodine can safely be instilled into the pleural for the purpose of pleurodesis. Pleural irrigation with antiseptics is used in adults with open drainage for chronic empyema and has been described in the acute management of paediatric pleural infection. This study will investigate the safety and usefulness of povidone-iodine pleural irrigation in 15 eligible patients recruited to the Pleural Infection Cohort Study (PICS) with acute pleural infection. A matched control group will be used and will be composed of 15 patients previously recruited to PICS without receiving povidone-iodine pleural irrigation.
Detailed Description
Pleural infection is a condition that requires hospitalization for management and is associated with significant in-hospital morbidity and mortality. Predictors of poor outcome include advancing age, poor nutrition, hospital-acquired infection and impaired renal function. Medical management is centred on appropriate antibiotic treatment and fluid drainage usually by the means of an intercostal tube. Up to 30% of patients fail medical treatment and referred for surgery. A recent systematic review of adults patient with pleural infection has shown that the demographics of patients with pleural infection are different in patients from high-income vs lower income countries; the latter being of younger age and lower comorbidity burden. However, the results of the review did not show significant differences in patient outcomes. The same systematic review pointed to the need for more data from patients residing in lower income countries given that the majority of data is contributed by studies from higher income countries. This platform study aims to prospectively investigate the incidence of pleural infection in a large tertiary centre gathering demographic and clinical data about patients recruited. In addition, the study will examine the different treatment offered and how this related to in-hospital outcomes (length of hospital stay, rate of referral to surgery and mortality). The study will be designed as a modified trial within cohort (TwiC) study. PICS will primarily aim to recruit patients prospectively to gather clinical and demographic data on patients admitted with pleural infection in addition to clinical data on tests performed and treatments received as part of the standard care. The in-patient outcomes will be recorded at the time of discharge data or death, whichever is earlier. Within the TWIC design, PICS will be a platform for recruiting patients to interventional trials for eligible patients within the cohort. As a planned sub-study, pleural antiseptics will be trialed within a subset of patients enrolled. The antiseptic povidone-iodine can safely be instilled into the pleural for the purpose of pleurodesis. Pleural irrigation with antiseptics is used in adults with open drainage for chronic empyema and has been described in the acute management of paediatric pleural infection. This sub-study will investigate the safety and usefulness of povidone-iodine pleural irrigation in 15 eligible adult patients recruited to PICS with acute pleural infection. A matched control group will be used and will be composed of 15 patients previously recruited to PICS without receiving povidone-iodine pleural irrigation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pleural Infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pleural irrigation with antiseptic
Arm Type
Experimental
Arm Description
Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.
Arm Title
No pleural irrigation
Arm Type
No Intervention
Arm Description
Standard care
Intervention Type
Drug
Intervention Name(s)
Povidone-Iodine pleural irrigation
Other Intervention Name(s)
Betadine
Intervention Description
Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
Primary Outcome Measure Information:
Title
Incidence of adverse events
Description
Number of subjects with any adverse event (new chest pain, fever, dyspnoea or oxygen desaturation)
Time Frame
Within 24 hours after the second application of the study medication
Title
Time to chest tube removal
Description
Number of days from tube insertion to tube removal
Time Frame
Up to 8 weeks
Secondary Outcome Measure Information:
Title
Time to defervescence
Description
Numbers of days until resolution of fever
Time Frame
Up to 8 weeks
Title
Length of hospital stay
Description
Number of days from admission/diagnosis until discharge from hospital
Time Frame
Up to 8 weeks
Title
Incidence of need for additional aspiration/tubes
Description
Number of patients requiring additional drainage procedures during hospital admission
Time Frame
Up to 8 weeks
Title
Incidence of medical treatment of failure
Description
Number of patients requiring surgical intervention
Time Frame
Up to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adult patients admitted to hospital with pleural infection and had a chest tube inserted for treatment of the infection. Pleural infection will be defined by the presence of one of the following: a) the presence of pus in the pleural space; b) positive pleural fluid gram stain or culture; or c) pleural fluid pH < 7.2 or pleural fluid glucose < 40 mg/dL in the setting of acute respiratory infection. Pleural collection is unilocular on pre-drainage imaging. Presence of septations on ultrasound examination is allowed. Exclusion Criteria: Known or suspected thyroid disease Allergy to iodine Persistent large collection on follow up imaging 24-48 of post tube insertion that requires another drainage procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maged Hassan, PhD
Organizational Affiliation
Alexandria Faculty of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alexandria University Faculty of Medicine
City
Alexandria
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
At completion of study assessments for the last recruited patients, data will be transferred from paper to electronic forms (spreadsheets) to allow statistical analysis. These spreadsheets will be stored securely after trial conclusion with the principal investigator and will be accessible to other members of the study team. Request to access study data by other teams will be expected via email and access will be granted by the principal investigator if the request is deemed reasonable.
IPD Sharing Time Frame
From published to study results up until five years after study completion
IPD Sharing Access Criteria
Access will be granted upon reasonable request via email to the principal investigator
Citations:
PubMed Identifier
20696693
Citation
Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii41-53. doi: 10.1136/thx.2010.137000. No abstract available.
Results Reference
background
PubMed Identifier
32675200
Citation
Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I, Heinink R, West A, Stanton AE, Holme J, Kastelik JA, Steer H, Downer NJ, Haris M, Baker EH, Everett CF, Pepperell J, Bewick T, Yarmus L, Maldonado F, Khan B, Hart-Thomas A, Hands G, Warwick G, De Fonseka D, Hassan M, Munavvar M, Guhan A, Shahidi M, Pogson Z, Dowson L, Popowicz ND, Saba J, Ward NR, Hallifax RJ, Dobson M, Shaw R, Hedley EL, Sabia A, Robinson B, Collins GS, Davies HE, Yu LM, Miller RF, Maskell NA, Rahman NM. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. Eur Respir J. 2020 Nov 26;56(5):2000130. doi: 10.1183/13993003.00130-2020. Print 2020 Nov. Erratum In: Eur Respir J. 2020 Dec 17;56(6):
Results Reference
background
PubMed Identifier
15745977
Citation
Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto TE, Woodhead MA, Lane DJ, Darbyshire JH, Davies RJ; First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005 Mar 3;352(9):865-74. doi: 10.1056/NEJMoa042473. Erratum In: N Engl J Med. 2005 May 19;352(20):2146.
Results Reference
background
PubMed Identifier
31391221
Citation
Cargill TN, Hassan M, Corcoran JP, Harriss E, Asciak R, Mercer RM, McCracken DJ, Bedawi EO, Rahman NM. A systematic review of comorbidities and outcomes of adult patients with pleural infection. Eur Respir J. 2019 Oct 1;54(3):1900541. doi: 10.1183/13993003.00541-2019. Print 2019 Sep.
Results Reference
background
PubMed Identifier
29224380
Citation
Kim SY, Flory J, Relton C. Ethics and practice of Trials within Cohorts: An emerging pragmatic trial design. Clin Trials. 2018 Feb;15(1):9-16. doi: 10.1177/1740774517746620. Epub 2017 Dec 11.
Results Reference
background
PubMed Identifier
22561614
Citation
Agarwal R, Khan A, Aggarwal AN, Gupta D. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012 Mar;135(3):297-304.
Results Reference
background
PubMed Identifier
16493154
Citation
Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006;3(1):75-80. doi: 10.1513/pats.200510-113JH.
Results Reference
background
Citation
Togo S, Ouattara MA, Sangaré I, Saye J, Touré CAS, Maiga IB, et al. Management for Pediatric Pleural Empyema in Resource-Poor Country: Is Chest Tube Drainage with Antiseptic Lavage-Irrigation Better than Tube Thoracostomy Alone? SS 2015;06(12):541-8.
Results Reference
background

Learn more about this trial

Antiseptic Irrigation for Pleural Infection

We'll reach out to this number within 24 hrs